Insider Trading Alert - AMAG, DXPE And JCOM Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, June 5, 2015, 80 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $368.50 to $15,580,000.00.

Highlighted Stocks Traded by Insiders:

AMAG Pharmaceuticals (AMAG) - FREE Research Report

Holmes Scott A, who is SVP, Finance and Treasurer at AMAG Pharmaceuticals, sold 22,516 shares at $68.88 on June 5, 2015. Following this transaction, the SVP, Finance and Treasurer owned 30,788 shares meaning that the stake was reduced by 42.24% with the 22,516-share transaction.

Wilson Kenneth H, who is SVP, Sales and Marketing at AMAG Pharmaceuticals, sold 5,388 shares at $68.77 on June 5, 2015. Following this transaction, the SVP, Sales and Marketing owned 25,000 shares meaning that the stake was reduced by 17.73% with the 5,388-share transaction.

The shares most recently traded at $71.15, up $2.38, or 3.35% since the insider transaction. Historical insider transactions for AMAG Pharmaceuticals go as follows:

  • 4-Week # shares sold: 834
  • 12-Week # shares sold: 834
  • 24-Week # shares sold: 834

The average volume for AMAG Pharmaceuticals has been 826,500 shares per day over the past 30 days. AMAG Pharmaceuticals has a market cap of $2.1 billion and is part of the health care sector and drugs industry. Shares are up 67.88% year-to-date as of the close of trading on Friday.

AMAG Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that focuses on maternal health, anemia, and cancer supportive care. The company has a P/E ratio of 11.3. Currently, there are 4 analysts who rate AMAG Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMAG - FREE

TheStreet Quant Ratings rates AMAG Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full AMAG Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

DXP (DXPE) - FREE Research Report

Vinson David C, who is Sr. V.P. at DXP, sold 1,300 shares at $41.16 on June 5, 2015. Following this transaction, the Sr. V.P. owned 13,626 shares meaning that the stake was reduced by 8.71% with the 1,300-share transaction.

The shares most recently traded at $41.33, up $0.17, or 0.41% since the insider transaction. Historical insider transactions for DXP go as follows:

  • 4-Week # shares bought: 4,100
  • 4-Week # shares sold: 1,900
  • 12-Week # shares bought: 4,100
  • 12-Week # shares sold: 1,900
  • 24-Week # shares bought: 4,100
  • 24-Week # shares sold: 1,900

The average volume for DXP has been 113,900 shares per day over the past 30 days. DXP has a market cap of $585.0 million and is part of the services sector and wholesale industry. Shares are down 18.29% year-to-date as of the close of trading on Friday.

DXP Enterprises, Inc. engages in distributing maintenance, repair, and operating (MRO) products, equipment, and services to industrial customers in the United States. It operates through three segments: Service Centers, Supply Chain Services, and Innovative Pumping Solutions. Currently, there are no analysts who rate DXP a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DXPE - FREE

TheStreet Quant Ratings rates DXP as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, poor profit margins, generally high debt management risk and generally disappointing historical performance in the stock itself. Get the full DXP Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

j2 Global (JCOM) - FREE Research Report

Zucker Nehemia, who is Chief Executive Officer at j2 Global, sold 3,001 shares at $67.25 on June 5, 2015. Following this transaction, the Chief Executive Officer owned 169,331 shares meaning that the stake was reduced by 1.74% with the 3,001-share transaction.

The shares most recently traded at $67.33, up $0.08, or 0.12% since the insider transaction. Historical insider transactions for j2 Global go as follows:

  • 4-Week # shares sold: 27,882
  • 12-Week # shares sold: 27,882
  • 24-Week # shares sold: 27,882

The average volume for j2 Global has been 278,800 shares per day over the past 30 days. J2 Global has a market cap of $3.2 billion and is part of the technology sector and internet industry. Shares are up 6.9% year-to-date as of the close of trading on Friday.

j2 Global, Inc. engages in the provision of Internet services worldwide. It operates through two segments, Business Cloud Services and Digital Media. The stock currently has a dividend yield of 1.81%. The company has a P/E ratio of 27.3. Currently, there are 2 analysts who rate j2 Global a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on JCOM - FREE

TheStreet Quant Ratings rates j2 Global as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full j2 Global Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug